ACICLOVIR VIATRIS aciclovir (as sodium) 250 mg powder for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

aciclovir viatris aciclovir (as sodium) 250 mg powder for injection vial

alphapharm pty ltd - aciclovir sodium dihydrate, quantity: 314.4 mg (equivalent: aciclovir, qty 250 mg) - injection, powder for - excipient ingredients: - aciclovir mylan (aciclovir sodium) is indicated for:,- promoting resolution of acute clinical manifestations of mucocutaneous herpes simplex virus infections in immunocompromised patients,- treatment of severe first episode primary or non-primary genital herpes in immune competent patients,- treatment of acute manifestations of varicella zoster virus infection in immunocompromised patients,- treatment of herpes zoster (shingles) in immune competent patients who show very severe acute local or systemic manifestations of the disease. (benefits can be expected in patients with rash duration shorter than 72 hours. the use of the intravenous infusion may be warranted in only a small subgroup of immune competent patients with shingles).,- treatment of herpes simplex encephalitis.

ACICLOVIR VIATRIS aciclovir (as sodium) 500 mg powder for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

aciclovir viatris aciclovir (as sodium) 500 mg powder for injection vial

alphapharm pty ltd - aciclovir sodium dihydrate, quantity: 628.8 mg (equivalent: aciclovir, qty 500 mg) - injection, powder for - excipient ingredients: - aciclovir mylan (aciclovir sodium) is indicated for:,- promoting resolution of acute clinical manifestations of mucocutaneous herpes simplex virus infections in immunocompromised patients,- treatment of severe first episode primary or non-primary genital herpes in immune competent patients,- treatment of acute manifestations of varicella zoster virus infection in immunocompromised patients,- treatment of herpes zoster (shingles) in immune competent patients who show very severe acute local or systemic manifestations of the disease. (benefits can be expected in patients with rash duration shorter than 72 hours. the use of the intravenous infusion may be warranted in only a small subgroup of immune competent patients with shingles).,- treatment of herpes simplex encephalitis.

Aciclovir 25mg/ml Concentrate for Solution for Infusion Ireland - English - HPRA (Health Products Regulatory Authority)

aciclovir 25mg/ml concentrate for solution for infusion

pfizer healthcare ireland - aciclovir sodium; aciclovir sodium - concentrate for solution for infusion - 25 milligram(s)/millilitre - nucleosides and nucleotides excl. reverse transcriptase inhibitors; aciclovir

ACICLOVIR AN aciclovir 800mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

aciclovir an aciclovir 800mg tablet blister pack

amneal pharma australia pty ltd - aciclovir, quantity: 800 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica - aciclovir tablets are indicated for use in adult patients for: (1) the treatment of first episode (primary or non-primary) genital herpes and the management of recurrent episodes of genital herpes in certain patients. (2) the treatment of acute attacks of herpes zoster (shingles) when the duration of rash is less than 72 hours. (3) the management of patients with advaned symptomatic hiv disease cd4 + counts < 150 x 10(6)/l). in accordance with details specified in the "indications" and the "dosage and administration" sections of the approved product information provided as attachment 1.

ACICLOVIR AN aciclovir 400mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

aciclovir an aciclovir 400mg tablet blister pack

amneal pharma australia pty ltd - aciclovir, quantity: 400 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica - aciclovir tablets are indicated for use in adult patients for: (1) the treatment of first episode (primary or non-primary) genital herpes and the management of recurrent episodes of genital herpes in certain patients. (2) the treatment of acute attacks of herpes zoster (shingles) when the duration of rash is less than 72 hours. (3) the management of patients with advanced symptomatic hiv disease (cd4 + counts < 150 x 10(6)/l). in accordance with details specified in the "indications" and the "dosage and administration" sections of the approved product information provided as attachment 1.

ACICLOVIR AN aciclovir 200mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

aciclovir an aciclovir 200mg tablet blister pack

amneal pharma australia pty ltd - aciclovir, quantity: 200 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica - aciclovir tablets are indicated for use in adult patients for: (1) the treatment of first episode (primary or non-primary) genital herpes and the management of recurrent episodes of genital herpes in certain patients. (2) the treatment of acute attacks of herpes zoster (shingles) when the duration of rash is less than 72 hours. (3) the management of patients with advanced symptomatic hiv disease (cd4 + counts < 150 x 10(6)/l). in accordance with details specified in the "indications" and the "dosage and adminsitration" sections of the approved product information provided as attachment 1.

ACICLOVIR ACCORD aciclovir 500 mg/20 mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

aciclovir accord aciclovir 500 mg/20 ml injection vial

accord healthcare pty ltd - aciclovir, quantity: 25 mg/ml - injection, solution - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - aciclovir intravenous infusion is indicated for the purpose of:,1. promoting resolution of acute clinical manifestations of mucocutaneous herpes simplex virus infections in immunocompromised patients.,2. treatment of severe first episode primary or non-primary genital herpes in immune competent patients.,3. treatment of acute manifestations of varicella zoster virus infection in immunocompromised patients.,4. treatment of shingles (varicella zoster virus infection) in immune competent patients who show very severe acute local or systemic manifestations of the disease. benefits can be expected in patients with rash duration shorter than 72 hours. the use of the intravenous infusion may be warranted in only a small subgroup of immune competent patients with shingles.,5. treatment of herpes simplex encephalitis.

ACICLOVIR ACCORD aciclovir 1000 mg/40 mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

aciclovir accord aciclovir 1000 mg/40 ml injection vial

accord healthcare pty ltd - aciclovir, quantity: 25 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide - aciclovir intravenous infusion is indicated for the purpose of:,1. promoting resolution of acute clinical manifestations of mucocutaneous herpes simplex virus infections in immunocompromised patients.,2. treatment of severe first episode primary or non-primary genital herpes in immune competent patients.,3. treatment of acute manifestations of varicella zoster virus infection in immunocompromised patients.,4. treatment of shingles (varicella zoster virus infection) in immune competent patients who show very severe acute local or systemic manifestations of the disease. benefits can be expected in patients with rash duration shorter than 72 hours. the use of the intravenous infusion may be warranted in only a small subgroup of immune competent patients with shingles.,5. treatment of herpes simplex encephalitis.

ACICLOVIR ACCORD aciclovir 250 mg/10 mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

aciclovir accord aciclovir 250 mg/10 ml injection vial

accord healthcare pty ltd - aciclovir, quantity: 25 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - aciclovir intravenous infusion is indicated for the purpose of:,1. promoting resolution of acute clinical manifestations of mucocutaneous herpes simplex virus infections in immunocompromised patients.,2. treatment of severe first episode primary or non-primary genital herpes in immune competent patients.,3. treatment of acute manifestations of varicella zoster virus infection in immunocompromised patients.,4. treatment of shingles (varicella zoster virus infection) in immune competent patients who show very severe acute local or systemic manifestations of the disease. benefits can be expected in patients with rash duration shorter than 72 hours. the use of the intravenous infusion may be warranted in only a small subgroup of immune competent patients with shingles.,5. treatment of herpes simplex encephalitis.

ACICLOVIR SANDOZ aciclovir 800mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

aciclovir sandoz aciclovir 800mg tablet blister pack

sandoz pty ltd - aciclovir, quantity: 800 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium starch glycollate type a; copovidone; magnesium stearate - adults; treatment of first episode (primary or nonprimary) genital herpes and the management of recurrent episodes of genital herpes in certain patients. treatment of acute attacks of herpes zoster (shingles) when the duration of rash is less than 72 hours. the management of patients with advanced symptomatic hiv disease (cd4+ counts <150 x 10 6/l). genital herpes initial episodes. the duration of viral shedding is reduced very significantly; the duration of pain and time to healing are also reduced. the promptness of initiation of therapy and/or the patient's prior exposure to herpes simplex virus may influence the degree of benefit from therapy. intravenous aciclovir should be considered in patients in whom prostration, cns involvement or inability to take oral medication requires hospitalisation and initiation or more aggressive management. aciclovir does not prevent the establishment of latency in initial episodes.,recurrent episodes. suppression. in patients with frequent recurrences, suppressive therapy